effects of raloxifene on bone metabolism in hemodialysis patients

Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients

Saito et al. (1) reported that raloxifene (RAL) suppressed bone turnover and increased the quantitative ultrasound (QUS) parameter, speed of sound (SOS) of the calcaneus in hemodialysis postmenopausal women with type 2 diabetes or without type 2 diabetes. Baseline bone turnover markers like serum cross-linked N-terminal telopeptides of type I collagen (NTX) and bone-specific alkaline phosphatas...

effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes

background osteoporosis and chronic kidney disease are common conditions in older adults, and often occur concurrently. bone disease is caused by increased bone turnover accompanying secondary hyperparathyroidism, and by factors such as bone metabolic disorder accompanying kidney disease and postmenopausal or age-related osteoporosis, even in hemodialysis patients. raloxifene is commonly used f...

Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes

BACKGROUND Osteoporosis and chronic kidney disease are common conditions in older adults, and often occur concurrently. Bone disease is caused by increased bone turnover accompanying secondary hyperparathyroidism, and by factors such as bone metabolic disorder accompanying kidney disease and postmenopausal or age-related osteoporosis, even in hemodialysis patients. Raloxifene is commonly used f...

Significant Effect of Raloxifene on Bone in Hemodialysis Patients

Attention should be drawn to the study by colleagues Saito O et al. published in the International journal of Endocrinology and Metabolism (1). The study suggests that raloxifene has a significant beneficial effect on bone in postmenopausal women with type 2 diabetes (2DM) undergoing hemodialysis (1). Hemodialysis patients are known to have a high risk of low bone mineral density and bone fract...

significant effect of raloxifene on bone in hemodialysis patients

raloxifene in hemodialysis patients